103 related articles for article (PubMed ID: 31234033)
1. Evaluation of lapatinib cytotoxicity and genotoxicity on MDA-MB-231 breast cancer cell line.
Abo-Zeid MAM; Abo-Elfadl MT; Gamal-Eldeen AM
Environ Toxicol Pharmacol; 2019 Oct; 71():103207. PubMed ID: 31234033
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors.
Widatalla SE; Korolkova OY; Whalen DS; Goodwin JS; Williams KP; Ochieng J; Sakwe AM
Carcinogenesis; 2019 Aug; 40(8):998-1009. PubMed ID: 30590459
[TBL] [Abstract][Full Text] [Related]
3. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
[TBL] [Abstract][Full Text] [Related]
5. Dillenia suffruticosa dichloromethane root extract induced apoptosis towards MDA-MB-231 triple-negative breast cancer cells.
Foo JB; Saiful Yazan L; Tor YS; Wibowo A; Ismail N; Armania N; Cheah YK; Abdullah R
J Ethnopharmacol; 2016 Jul; 187():195-204. PubMed ID: 27131434
[TBL] [Abstract][Full Text] [Related]
6. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
El Guerrab A; Zegrour R; Nemlin CC; Vigier F; Cayre A; Penault-Llorca F; Rossignol F; Bignon YJ
PLoS One; 2011; 6(9):e25080. PubMed ID: 21966417
[TBL] [Abstract][Full Text] [Related]
7. Hypericin Induces Apoptosis in MDA-MB-175-VII Cells in Lower Dose Compared to MDA-MB-231.
Abbasi Gamasaee N; Radmansouri M; Ghiasvand S; Shahriari F; Zare Marzouni H; Aryan H; Jangholi E; Javidi MA
Arch Iran Med; 2018 Sep; 21(9):387-392. PubMed ID: 30221528
[TBL] [Abstract][Full Text] [Related]
8. The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.
Tam S; Al-Zubaidi Y; Rahman MK; Bourget K; Zhou F; Murray M
Pharmacol Rep; 2022 Oct; 74(5):998-1010. PubMed ID: 35908023
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.
Mu Y; Sun D
Med Sci Monit; 2018 Aug; 24():5811-5819. PubMed ID: 30125265
[TBL] [Abstract][Full Text] [Related]
10. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
11. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
El Guerrab A; Bamdad M; Kwiatkowski F; Bignon YJ; Penault-Llorca F; Aubel C
Oncotarget; 2016 Nov; 7(45):73618-73637. PubMed ID: 27655662
[TBL] [Abstract][Full Text] [Related]
12. Dendrosomal nanocurcumin and exogenous p53 can act synergistically to elicit anticancer effects on breast cancer cells.
Baghi N; Bakhshinejad B; Keshavarz R; Babashah S; Sadeghizadeh M
Gene; 2018 Sep; 670():55-62. PubMed ID: 29753810
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells.
Hsia TC; Tu CY; Chen YJ; Wei YL; Yu MC; Hsu SC; Tsai SL; Chen WS; Yeh MH; Yen CJ; Yu YL; Huang TC; Huang CY; Hung MC; Huang WC
Mol Pharmacol; 2013 Apr; 83(4):857-69. PubMed ID: 23355539
[TBL] [Abstract][Full Text] [Related]
14. Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity.
Shrivastava R; Trivedi S; Singh PK; Asif M; Chourasia MK; Khanna A; Bhadauria S
Biochem Biophys Res Commun; 2018 Sep; 503(2):677-683. PubMed ID: 29908185
[TBL] [Abstract][Full Text] [Related]
15. [Effects of mammalian-target-of-rapamycin pathway on lapatinib resistance in breast cancer MDA-MB-231 cells].
Wang JD; Wang QS; Bai YZ; Kou DQ; Li XR; Chen L; Li R
Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(24):1915-7. PubMed ID: 24124748
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod sensitizes EGFR wild‑type non‑small cell lung cancer cells to lapatinib or sorafenib and induces cell cycle arrest.
Ota K; Okuma T; Lorenzo A; Yokota A; Hino H; Kazama H; Moriya S; Takano N; Hiramoto M; Miyazawa K
Oncol Rep; 2019 Jul; 42(1):231-242. PubMed ID: 31059070
[TBL] [Abstract][Full Text] [Related]
17. Conjugates Derived from Lapatinib Derivatives with Cancer Cell Stemness Inhibitors Effectively Reversed Drug Resistance in Triple-Negative Breast Cancer.
Wang Y; Lv Z; Chen F; Wang X; Gou S
J Med Chem; 2021 Sep; 64(17):12877-12892. PubMed ID: 34435487
[TBL] [Abstract][Full Text] [Related]
18. Indole-3-carbinol-induced death in cancer cells involves EGFR downregulation and is exacerbated in a 3D environment.
Moiseeva EP; Fox LH; Howells LM; Temple LA; Manson MM
Apoptosis; 2006 May; 11(5):799-812. PubMed ID: 16532375
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study.
Jabbarzadeh Kaboli P; Leong MP; Ismail P; Ling KH
Pharmacol Rep; 2019 Feb; 71(1):13-23. PubMed ID: 30343043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]